Substitute for PTO-1390 (Rev. 07-2005) " Approved for use through 3/31/2007. 'ON	Transmittal Letter to the United States Designated/Elec	ted Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"
Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elect Approved for use through 3/31/2007. 'OMB 0651-0021 U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER
		21443P
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
		10/560771
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US2004/018718	June 10, 2004	June 17, 2003
TITLE OF INVENTION CYCLOHEXYLGLYCINE DERIVAT OF DIABETES APPLICANT(S) FOR DO/EO/US	TIVES AS DIPEPTIDYL INHIBITOR	RS FOR THE TREATMENT OR PREVENTION
Scott D. Edmondson, Anthony Mastra	cchio, Emma R. Parmee	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and		
other information:	omica states beignated, bietta o	thee (Borzor os) the following Items und
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
3. This is an express request to include items (5), (6), (9) an	•	s [35 U.S.C. 371(f)]. The submission must
4. The US has been elected (PCT Article 31).		
5. X A copy of the International Application as filed [35 U.S.C. 371(c)(2)]		
a. is attached hereto (required only if not communicated by the International Bureau).		
b. has been communicated by the International Bureau.		
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).		
6. An English language transla a. is attached hereto	tion of the International Application as	s filed [35 U.S.C. 371(c)(2)].
b. has been previously submitted under 35 U.S.C. 154(d)(4).		
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).		
b. have been communicated by the International Bureau.		
c. have not been made; however, the time limit for making such amendments has NOT expired.		
d. have not been made and will not be made.		
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].		
9. X An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].		
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT		
Article 36 [35 U.S.C. 371(c) Items 11 to 20 below concern other	(5)]. · document(s) or information include	ed:
	Statement under 37 CFR 1.97 and 1.98	
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. X A preliminary amendment.		
14. An Application Data Sheet u	inder 37 CFR 1.76.	
15. A substitute specification.		
16. A power of attorney and/or of	change of address letter.	
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.		
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).		
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).		
20. Other items or information:		

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"

Approved for use through 3/31/2007. OMB 0651-0021 INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 21443P PCT/US2004/018718 The following fees are submitted: **CALCULATIONS** PTO USE ONLY 21. Basic national fee......\$300 \$300.00 Examination fee (37 CFR 1.492(c)) 22. If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)......\$0 All other situations......\$200 \$200.00 Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an \$100.00 International Searching Authority......\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB\$400 TOTAL OF 21, 22 and 23= \$600.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Number of each additional 50 or fraction **Total Sheets** Extra Sheets RATE thereof (round up to a whole number) 54 - 100 = 0 /50 0 = 0\$250.00 X \$0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)] **CLAIMS** NUMBER FILED **NUMBER EXTRA RATE** Total Claims 22 X \$100.00 -20 =2 \$50.00 Independent Claims X -3 =\$0.00 0 \$200.00 MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$360.00 \$700.00 TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). TOTAL NATIONAL FEE \$700.00 Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property. TOTAL FEES ENCLOSED \$700.00 Amount to be refunded: Amount to be charged: A check in the amount of \$ _____ to cover the above fees is enclosed. Please charge my Deposit Account No. 13-2755 in the amount of \$700.00 to cover the above fees. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Customer No. 000210 MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970 Philippe L. Durette NAME DATE: December 13, 2005 35,125 PHONE #: (732) 594-4568 REGISTRATION NUMBER

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371" Approved for use through 3/31/2007. OMB 0651-0021

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:

21443P

International Appln No.:

PCT/US2004/018718

International Filing Date:

10 June 2004

Priority Date:

17 June 2003

Title:

CYCLOHEXYLGLYCINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THe TREATMENT OR PREVENTION OF DIABETES

Inventors:

(-

Scott D. Edmondson Anthony Mastracchio Emma R. Parmee

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT December 13, 2005

EXPRESS MAIL NO. EV 660609055 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.